Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

Abstract Purpose The choice of continuous renal replacement therapy (CRRT) anticoagulation program for patients at high risk of bleeding has always been a complex problem in clinical practice. Clinical regimens include regional citrate anticoagulation (RCA) and nafamostat mesylate (NM). This study a...

Full description

Bibliographic Details
Main Authors: Dan Liu, Jian Zhao, Hui Xia, Shi Dong, Songjuan Yan, Yugang Zhuang, Yuanzhuo Chen, Hu Peng
Format: Article
Language:English
Published: BMC 2024-01-01
Series:European Journal of Medical Research
Subjects:
Nafamostat mesylate
Regional citrate anticoagulation
Anticoagulation
Continuous renal replacement therapy
High risk of bleeding
Online Access:https://doi.org/10.1186/s40001-024-01660-7

Internet

https://doi.org/10.1186/s40001-024-01660-7

Similar Items